Log in Free sign up

Eloxx Pharmaceuticals (ELOX) News and press releases

News

From Benzinga Pro

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

Eloxx Pharmaceuticals: Q1 Earnings Insights

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Eloxx Pharmaceuticals Q1 EPS $(0.13) Up From $(0.22) YoY

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(0.13) per share. This is a 40.91 percent increase over losses of $(0.22) per share from the same period last year.

HC Wainwright & Co. Maintains Neutral on Eloxx Pharmaceuticals, Lowers Price Target to $0.5

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Andrew Fein maintains Eloxx Pharmaceuticals (NASDAQ:ELOX) with a Neutral and lowers the price target from $1 to $0.5.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

12 Health Care Stocks Moving In Wednesday's After-Market Session

Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 721 companies achieved new lows for the year.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 431 companies hit new 52-week lows.

Eloxx to Test Its Lead Product Candidate, ELX-02, In Rare Kidney Disease

Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Movers, Trading Ideas, General

Eloxx Pharmaceuticals Inc (NASDAQ: ELOX)

Recap: Eloxx Pharmaceuticals Q4 Earnings

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Eloxx Pharmaceuticals Q4 EPS $(0.14) Misses $(0.12) Estimate

Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 6.67 percent increase over losses of $(0.15) per share

Eloxx Pharma Highlights New Development Program For ELX-02 For Treatment Of Alport Syndrome

Biotech, News, FDA, General

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of

Eloxx Pharma Wins $15.9M Grant From Cystic Fibrosis Foundation

Biotech, News, FDA, General

Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from cystic fibrosis Phase 2 expansion treatment arms evaluating

Press releases

From Benzinga Pro

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Earnings, Press Releases

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Health Care, Press Releases, General

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of